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Acute renal failure is a severe complication of lower extremity major arterial reconstruc-
tions, which could even be fatal. Levosimendan is a dual-acting positive inotropic and vaso-
dilatory agent, which is suspected to have protective effects against cardiac ischemia.
However, there is no data available on lower limb or remote organ ischemic injuries there-
fore the aim of the study was to investigate the effect of levosimendan on lower limb ische-
mia-reperfusion injury and the corollary renal dysfunction.
Methods
Male Wistar rats underwent 180 min bilateral lower limb ischemia followed by 4 or 24 hours
of reperfusion. Intravenous Levosimendan was administered continuously (0.2μg/bwkg/
min) throughout the whole course of ischemia and the first 3h of reperfusion. Results were
compared with sham-operated and ischemia-reperfusion groups. Hemodynamic monitor-
ing was performed by invasive arterial blood pressure measurement. Kidney and lower
limb muscle microcirculation was registered by a laser Doppler flowmeter. After 4h and 24h
of reperfusion, serum, urine and histological samples were collected.
Results
Systemic hemodynamic parameters and microcirculation of kidney and the lower limb sig-
nificantly improved in the Levosimendan treated group. Muscle viability was significantly
preserved 4 and 24 hours after reperfusion. At the same time, renal functional laboratory
tests and kidney histology demonstrated significantly less expressive kidney injury in Levo-
simendan groups. TNF-α levels were significantly less elevated in the Levosimendan group
4 hours after reperfusion.
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Conclusion
The results claim a protective role for Levosimendan administration during major vascular
surgeries to prevent renal complications.
Introduction
Lower limb ischemic injuries (such as acute limb ischemia or evenmajor vascular surgery on
lower limb arteries) may represent serious clinical situations where profound cell destructions
lead to substantial hemodynamic disturbances, systemic inflammatory changes and conse-
quentially, severe multi-organ injuries [1]. Critical ischemic injury of the lower limbs might
result in the loss of the limb or death, with mortality rates ranging from 15% to 20%.[2] Early
detection of ischemia or deterioration of the injury is essential for survival. However, revascu-
larization can result in further tissue damage due to reperfusion injury. A handful of surgical
techniques and pharmacological approaches have been extensively investigated concerning the
attenuation of IR injury.
Levosimendan is described as a dual-acting positive inotropic and vasodilatory agent devel-
oped for treatment of severe acute heart failure.[3] The agent exerts its positive inotropic effect
through sensitizing the myocardium to Ca2+ by binding to and stabilizing the Ca2+ saturated
troponin C.[4] The vasodilatory effect is related to the potential to open the ATP-sensitive K+
(KATP) channels, localized in the sarcolemma of vascular smoothmuscle cells in small resis-
tance vessels[5] as well as in the venous side of the circulation[6], leading to reduced cardiac
afterload and preload.[7] In the large conductance vessels, other (voltage-gated[8] and Ca2
+-dependent[9]) subtypes of potassium channels have also been proposed to be opened by the
drug though with equivocal clinical relevance.
Levosimendan has also been demonstrated to be an agonist of the mitochondrial type of
KATP (mitoKATP) channels.[10] Mitochondria play a central role in the pathogenesis of the I-R
injury, and mitoKATP channels (located in the inner membrane of the organelle) have also
been introduced as central mediator components in the ischemic protective methods. During
ischemic preconditioning (IPC) and ischemic postconditioning (IPostC) several parallel signal-
ling pathways converge at the level of mitochondria and lead to the opening of mitoKATP chan-
nels resulting in the stabilization of mitochondrial membrane thus limiting mitochondria
mediated intracellular damage, therefore preventing cell death.[11–15]
Latest experimental data address some other effects of levosimendan, such as immunomod-
ulatory, anti-inflammatory,[16] platelet aggregation inhibitory[17] and anti-apoptotic action.
[18] The exact mechanisms of how the agent is able to achieve these positive effects are not yet
fully understood, nevertheless these all may contribute to the cardioprotective and positive
hemodynamic effects of the drug.
In spite of the great clinical importance of lower limb ischemic conditions, levosimendan
previously has not been applied to limit injuries in such cases, therefore the aim of the present
investigation was to apply levosimendan treatment in an experimentalmodel of prolonged
lower limb ischemia-reperfusion in which postoperative kidney dysfunction and systemic cir-
culatory failure develop. Further goal was to assess the effects of the agent on local and systemic
postischemic complications. Our previous investigations on the same model revealed that the
technique of ischemic postconditioning can exert a protective effect on postoperative renal fail-
ure possibly through a mechanism involving mitoKATP opening,[19] which implies that levosi-
mendan—acting on the same effector—might have similar effects.
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Materials and Methods
Male Wistar rats weighing 200–250 grams were used (Semmelweis University, Central Animal
Facility, Budapest, Hungary). All investigations made on animals conformed to the guidelines
of the US National Institute of Health on topic of use and care of experimental animals (Publi-
cation No. 85–23, revised 1996; MD, USA) also approved by the Committee on Animal Experi-
mentation of Semmelweis University, Hungary (Permit No: 22.1/2409/3/2011).
Animals were kept under pathogen-free conditions, in 12-hour day-night cycles, at 22–24°C
and had unlimited access to commercial pellets and water until 12 hours before operation,
when only water was provided. Each experiment was performed at the same time of day to
avoid any effects of circadian changes.
Experimental design
Rats (n = 44) were distributed randomly into two main groups defined by the proposed length
of reperfusion (4 and 24 hours), and were further divided into three subgroups according to
the operation type (Sham-operation, IR and Levosimendan, 6-8-8 animals each group, respec-
tively). (Fig 1)
Animals were anesthetized with intraperitoneal injection of ketamine (75 mg/bwkg) and
xylasine (7.5 mg/bwkg). Deep anesthesia was maintained by continuous intravenous adminis-
tration of anesthetics (ketamine and xylasine; 25 and 2.5 mg/bwkg/h respectively) and saline
solution (3 ml/bwkg/h) via a 22-gauge polyethylene catheter (Harvard Apparatus, Holliston,
MA) placed into the right jugular vein. Another polyethylene catheter was inserted into the
Fig 1. Study design and groups. Male Wistar rats underwent 180 min bilateral lower limb ischemia
followed by 4 or 24 hours of reperfusion. Intravenous Levosimendan was administered continuously (0.2μg/
bwkg/min) throughout the whole course of ischemia and the first 3h of reperfusion, while IR and Sham
groups received only vehicle (Saline infusion).
doi:10.1371/journal.pone.0163675.g001
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right carotid artery connected to a blood pressure gauge to register mean arterial blood pres-
sure (MAP) and heart rate (HR).
Through medianlaparotomy, the infrarenal section of the abdominal aorta was prepared. A
laser Doppler flow probe (DP1T surface probe, Moor Instruments Ltd, London, UK) was
placed on identical localizations on the ventral surface of the left kidney as well as on the sur-
face of the left biceps femoris muscle through a 10 mm long incision on the skin and fascia as
describedpreviously.[19]
After a 30 minutes recovery period and baseline hemodynamicmeasurements, the infrare-
nal aorta was crossclamped with an atraumatic microvascular clip (Aesculap YASARGIL
FT260T; B.Braun Melsungen AG, Melsungen, Germany), and the abdominal cavity was cov-
ered by a plastic wrap to prevent fluid loss by evaporation. 5 minutes prior to ischemia, 60 IU
Na-heparin was administered intravenously. 3 hours of bilateral lower limb ischemia was
established (IR and Levosimendan groups). At the end of ischemia, the microvascular clip was
removed and reperfusionwas allowed. (Animals in the 4 hours’ reperfusion group were kept in
narcosis with further registration of hemodynamics and microcirculation.All other animals
were allowed a survival time of 24 hours.) Animals were sacrificed at the indicated time points
(4 or 24 hours after reperfusion) by exsanguination via right ventricular puncture, then muscle
(right anterior tibial), right kidney and blood samples were collected.
Levosimendan (Simdax1 2.5mg/ml, OrionPharma Ltd, Hungary), dissolved in 5g/100ml
glucose solution, was administered as a continuous intravenous infusion (0.2 μg/bwkg/min,
0,48ml/bwkg/hwith the dilution of 25 μg/ml, through the left jugular vein), initiated at the
onset of infrarenal aortic clamping and throughout the whole course of ischemia and the first 3
hours of reperfusion (6 hours in total). In the first 10 minutes of administration, an increased
(bolus) dose of 12 μg/bwkg levosimendanwas given to mimic the clinically recommended
administration protocol. IR and Sham-operated groups received only the vehicle (5g/100ml
glucose solution) with the application of the same protocol.
Urine samples were collected throughout a 30 minutes’ baselinemeasurement period before
ischemia to serve as a control. In animals subjected to 4 hours of reperfusion, another set of
urine samples were collected from the start of the second hour on after reperfusion (i.e. for 3
hours) and their volume was measured. From the 24-hour-reperfusion animals, urine samples
were taken through laparotomy by a needle puncture of the urinary vesicle.
Sham-operated animals underwent the same procedure described above except for the aor-
tic occlusion.
Systemic hemodynamics
Pressure signals were measured continuously (200 data per second) with a blood pressure
gauge (Kent Scientific Corporation, Torrington, CT). A computerized data-acquisition system
(DasyLab V9.00.02 software, National Instruments Corporation,Austin, TX) calculated and
registered heart rate (HR), systolic (SBP) and diastolic (DBP) and mean arterial (MAP) blood
pressure every 5 seconds.
Parameters underwentmathematical transformations as describedpreviously by our group
[19] using c++ (ISO/IEC14882 standard) code edited in Code::Blocks (10.05 rev6283mCode::
Blocks Team, USA) and compiled by MinGW (2012., mingw.org). For eliminating the inciden-
tal measurement errors and failures due to external influences, some criteria were defined and
enforced with the exclusion of data that failed these preset conditions. As criteria, upper and
lower bounds for SBP, DBP and HR values were adjusted for each individual animal. Sudden
changes in these parameters were also considered as results of external factors. Thus data were
cancelled and replaced when exceeding a preset percentage of difference compared to the last
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accepted value. All invalidated and deleted data were replaced by the last known accepted val-
ues. When replacing multiple consecutive faulty values, the percentage interval of admissible
parameters was increased exponentially with respect to the duration of the measurement error.
The resulting sequences of data underwent furthermathematical transformations (Gaussian
smoothing) for the purpose of calculations and better comparability of the individual animals.
For each parameter, a mean of nearby values weighted with Gaussian functionwas considered.
For detailed analysis of the blood pressure and heart rate data, the following calculations
were performed:
1. Similarly to ‘shock index’, at each time point the quotient of HR and SBP was calculated and
the mean was taken for both the period of ischemia and reperfusion.Dividing this mean of
reperfusion by the mean of ischemia, a ratio was determined that is characteristic for the
hemodynamic changes occurring after revascularization and the efficacy of the given ani-
mal’s compensative mechanisms.
2. To characterize and quantify the observeddrop of blood pressure at revascularization, the
lowest mean arterial pressure (MAP) was identifiedwithin the first 20 min of the reperfu-
sion period. The time intervals were determined between this time point and the beginning
of reperfusion, as well as the degree of this drop expressed as percentage of the last registered
MAP of the ischemic period.
3. After the drop of blood pressure, a gradual rise was apparent in each animal reaching again
a plateau state. With help of ‘IF function’ of Microsoft Excel (Microsoft Corporation, Red-
mond, WA, USA), the point in time was determinedwhenmean arterial blood pressure
reaches the beginning of the plateau phase.
Microcirculation
Kidney and lower limb muscle microcirculationwas measured by a laser Doppler flowmeter
(LDF; Moor DRT4, 2 mW laser power at λ = 632.8 nm; DP1T surface probe, Moor Instruments
Ltd, London, UK). Data were registered (at a sampling rate of 10/min) with the manufacturer’s
software (MoorSoft for Windows v1.2, Moor Instruments Ltd, London, UK). To eliminate the
variations among the baseline flow of the individual animals, all measured flux was normalized
to and expressed as a percentage of mean of baseline flux. Two parameters were calculated:
reperfusion area (RA, integral of the reperfusion segment of the graphs, proportional to the
average blood-flowduring reperfusion), and the plateau maximum (PM, mean of the last, pla-
teau-shaped 10 min of the reperfusion-slope).[20]
Histology
Muscle and kidney samples were fixed in 4% neutral-buffered formalin for a day, dehydrated
and embedded in paraffin. Three μm thin sections were cut and stained with hematoxylin and
eosin. Histological examinations were carried out with light microscopy (Olympus BX50
microscope equipped with Olympus DP70 camera; Olympus Corporation, Tokyo, Japan) by a
trained pathologist in a blinded fashion. The pathological alterations were considered as fol-
lows: Muscle: (1) preservation of the striae of the skeletal muscle (2) preservation of the cell
nuclei (3) intracellular vacuolisation (4) muscle fiber ripple, blurring (5) precipitation of the
contractile proteins (6) homogeneity of cytoplasmic staining. Kidney:(1) glomerular condition
(2) swelling of tubule cells, hydropic degeneration of kidney tubular epithelium and vacuolisa-
tion (3) precipitation in tubule lumens (4) presence of absorbed precipitate (5) detached epi-
thelial cells (6) dilation of the vessels (stasis).
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Muscle viability
Part of the samples from the anterior tibial muscle were snap frozen in liquid nitrogen and
stored at -80°C until further processing. 3 μm thick cross sections were cut in cryostat, then
stained with NADH tetrazolium-reductase immonohistochemistry as described earlier.[21]
Viability assessment was performed on the NADH-tetrazolium reductase stainedmuscles with
the use of a morphometricmethod developed by our team.[22] The ratio of stained area and
the total muscle fiber area was determinedwhich correlates with the viability of the muscle
fibers. The final result is expressed as a percentage of the values of untreated control muscles.
Laboratory measurements
Serum (centrifuged) and urine samples were snap-frozen in liquid nitrogen immediately after
harvest and stored at -80°C. Serum creatinine, carbamide, sodium concentration, urine vol-
ume, creatinine, and sodium concentration were measured. Analysis was performed by an
automated clinical chemistry analyzer (BeckmanCoulter AU480/2011, BeckmanCoulter Inc,
Brea, CA). Creatinine clearance ([Creatinine]urinary x urine flow [Creatinine]serum), Serum
[carbamide]/[creatinine] ratio, fractional sodium excretion (FENa) ([Na+]urinary × [Creatini-
ne]serum) ([Na+]serum × [Creatinine]urinary) × 100) and renal failure index (RFI) ([Na+]urinary
× [Creatinine]urinary [Creatinine]serum) were calculated.
SerumTNF α levels were assessed by sandwich ELISA kits (R&D Systems, Minneapolis,MN).
Mouse TNF-α standard (200mL, in serially decreasing dilutions: 750–23.4 pg/mL), and 200 mL
of TNF-α conjugate (polyclonal antibody to TNF-α conjugated with horseradish peroxidase) was
added to each well in the ELISAmicrotiter plate, and incubated. A color reaction developedwith
a substrate containing equal volumes of stabilized hydrogen peroxide and tetramethyl benzidine
(stopped after 20 min by addition of hydrochloric acid). Absorbance was measured at 450 nm.
Each optical absorbance value was calculated as a percentage of the average optical absorbance.
Statistical analysis
Data were analyzed using IBM SPSS Statistics Version 22 (IBMCorporation,Armonk, NY). All
values are expressed as means ± S.D. For every group of animals the assumption of normality of
each measured parameter’s distributionwas tested using Kolmogorov-Smirnov statistic, then
Levene’s tests for homogeneity of variances were performed.Accordingly, in cases when homo-
geneity of variances was assumed, one way ANOVA (analysis of variance) tests were calculated
with Scheffe’s post hoc test for between groups comparisons.When heterogenity of variances
was assumed, Brown-Forsythe test was performedwith Games-Howell post hoc multiple com-
parisons. Any differences were considered statistically significant with p values less than 0.05.
Results
Systemic hemodynamics
No significant alterations could be found during the whole registration in the Sham operated
group regarding both heart rate (HR) and mean arterial blood pressure (MAP). Blood pressure
elevated significantly (p<0.001) after aortic occlusion and remained elevated throughout the
period of ischemia in the IR group as compared to the Sham operated group. Levosimendan
administration withheld this elevation until the 3rd hour of ischemia. Reperfusion resulted in a
drop in MAP in both groups (IR and Levosimendan) compared to the ischemic values.
HR was significantly elevated during ischemia in the IR group, as measured after the 1st
(p = 0.004), 2nd (p = 0.002) and 3rd (p<0.001) hours versus Sham. Reperfusion resulted in
another significant (p<0.001) increase in HR then remained elevated thereafter. Levosimendan
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administration resulted in significantly less elevated HR compared to the IR group both during
ischemia and reperfusion (Fig 2) as measured after the 1st (p = 0.016), 2nd (p = 0.017), 3rd
(p = 0.023), 5th (p = 0.049), 6th (p = 0.038), and 7th (p = 0.025) hours.
1. Calculated ‘shock-index’ was higher for the period of reperfusion than for ischemia in the
IR group (quotient>1). This was also the case in the Levosimendan group, with no statisti-
cally significant difference between the two groups (1.09±0.25 vs. 1.07±0.30, p>0.05).
2. The lowest systolic blood pressure within the first 20 min of reperfusion occurred at 6.00
±2.86 min in the Levosimendan, and at 7.37±4.97 min after revascularization in the IR
group, which did not differ statistically (p>0.05). This drop of blood pressure was greater in
the IR group (16.61±3.61% of the last registered systolic blood pressure of the ischemic
time) than in the Levosimendan group (8.56±8.22%), though because of the high standard
deviation, the difference was found non-significant.
3. After the drop of the blood pressure, the pressure curves reached the plateau phase within a
similar time interval in both the Levosimendan and the IR group (IR: 17.53±11.23 min vs.
Levosimendan: 17.42±19.83 min after revascularization, p>0.05). (Fig 3)
Microcirculation
Sham operation resulted in no alterations in either kidney or skeletal muscle flow throughout
the experiment. Kidneymicrocirculation remained at the baseline level after clamping of the
Fig 2. Heart rate. Heart rate increased significantly from the baseline during ischemia remained elevated during reperfusion in the IR (ischemia-
reperfusion) group (broken line). Levosimendan administration resulted in significantly less elevated HR compared to the IR group during both
ischemia and reperfusion (unbroken line). Sham operated group is marked with a dotted line. Values are expressed as means ± SD, †: p<0.01 vs.
Sham, ‡: p<0.001 vs. Sham, $: p<0.05 vs. IR, §: p<0.01 vs. IR.
doi:10.1371/journal.pone.0163675.g002
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infrarenal aorta in both IR and Levosimendan groups. After revascularization, flux deteriorated
gradually in the IR group while levosimendan administration was able to maintain renal corti-
cal microcirculation at a significantly higher level (PM: IR: 78.02±12.63% vs. Levosimendan:
96.90±4.67%, p = 0.009; RA%: IR: 82.91±9.75% vs. Levosimendan: 98.84±1.85%, p = 0.004),
resembling the values measured in the Sham operated group. (Fig 4)
Muscle microcirculation dropped at the onset of aortic occlusion in both the IR and Levosi-
mendan groups. At the onset of reperfusion,microcirculation increased to about 100% of base-
line flux in the Levoismendan group, in contrast to IR group where it reached only 80% of
baseline values. Levosimendan treatment caused significant amelioration in everymicrocircu-
latory parameters. (PM: IR: 62.87±14.58% vs. Levosimendan: 89.25±6.70%, p = 0.004; RA%:
IR: 66.01±14.92% vs. Levosimendan: 90.26±6.55%, p = 0.006). (Fig 5)
Histology
Light microscopy and HE staining was not able to detect any definitive histopathological
lesions in the samples taken from the tibial anterior muscle in any groups at any measured
time points.
Kidney samples showed signs of acute tubular injury in the IR group with swollen, vacuo-
lized tubular cells and precipitated hyaline-cylinders within the tubular lumina after 4 hours of
Fig 3. Mean arterial pressure. Blood pressure elevated significantly after aortic clamping and remained elevated throughout the ischemic period in
the IR (ischemia-reperfusion) group (broken line). Levosimendan treatment withheld this elevation during ischemia (unbroken line). At the onset of
reperfusion a significant drop occurred, but after that, mean arterial pressure increased and then remained elevated in both IR and Levosimendan
groups without significant difference between the groups. Sham operated group is marked with a dotted line. Values are expressed as means ± SD,
†: p<0.01 vs. Sham, ‡: p<0.001 vs. Sham, §: p<0.001 vs. IR.
doi:10.1371/journal.pone.0163675.g003
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reperfusion. 24 hours after aortic declamping slightly milder histological damage could be
observed in the IR group compared to 4 hours of reperfusion. Levosimendan administration
resulted in a lesser degree of histological injury at both examined reperfusion intervals com-
pared to the corresponding IR group (qualitative analysis).
Muscle viability
4 hours after revascularization, a marked decrease in viability was detected in the IR group, as
well as results showed no regeneration even after 24 hours of reperfusion. Levosimendan
administration resulted in significantly preserved (p<0.001) viability compared to the IR
group at both measured time points (4 and 24 hours), however the values of the Levosimendan
group failed to reach the levels of the sham operated animals. (4 hours: Sham 99.203±2.625, IR:
36.601±6.507 vs Levosimendan: 60.746±3.932 p<0.001; 24 hours: Sham: 99.164±2.663, IR:
39.666±4.097 vs Levosimendan: 66.593±4.732 p<0.001). (Fig 6)
Laboratory measurements
At the end of the fourth hour of reperfusion, kidney injury induced renal hypofunctionwas evi-
dent in the IR group according to markedly elevated serum creatinine levels (p<0.001), as well
as creatinine clearance rates (p<0.001), and reperfusion urine volumes also showed a signifi-
cant (p = 0,0??) deterioration of renal function compared to the sham operated group. Mean-
while in the 4h survival levosimendan treated group, significantly (p = 0.006) less expressive
kidney injury could be observed.
Fig 4. Kidney cortex microcirculation measured with laser Doppler flowmeter. Measured flux is expressed as a percentage of the baseline flux
before the aortic clamping. Flux remained at the baseline level after clamping of the infrarenal aorta in all three animal groups. After revascularization
of the limbs, a constant impairment of the kidney cortex microcirculatory flux was observed in the ischemia-reperfusion (IR) group (marked with a
broken line), while flux was preserved in the Levosimendan (unbroken line) and the Sham (dotted line) groups. Values are expressed as
means ± SD, ‡: p<0.001 vs. Sham, §: p<0.001 vs. IR.
doi:10.1371/journal.pone.0163675.g004
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Serum carbamide/creatinine ratio and the fractional sodium excretion indicated a tubular
type kidney failure in the IR group, whereas the values in the Levosimendan group were not
characteristic for any type of kidney failure, according to regulardefinitions.Differences were
significant (p<0.001). Renal failure index and fractional sodium excretion indicated persistent
kidney damage at the 24th hour after reperfusionwith significantly lower values in the Levosi-
mendan group (p<0.001) (Table 1).
TNF-α concentrations were significantly increased in the IR group compared to the Sham-
operated group (p<0.001) after 4 hours of reperfusion. Levosimendan administration was able
to significantly reduce serumTNF-α levels compared to the IR group at this measurement
point (p<0.001). After 24 hours of reperfusion no differences (IR vs. SHAM:???; IR vs. Levo:
p = 0.225) could be observedamong the three experimental groups in serumTNF-α concentra-
tions (Fig 7).
Discussion
Prolonged lower limb ischemic conditions like acute critical limb ischemia with surgical revas-
cularization therapy as well as major vascular surgeries of the lower limb arteries with cross-
clamping of the abdominal aorta might result in profound ischemia-reperfusion injury of the
Fig 5. Muscle microcirculation measured with laser Doppler flowmeter. Measured flux is expressed as a percentage of the baseline flux before the
aortic clamping. Flux dropped at the onset of aortic occlusion in both the ischemia-reperfusion (IR, marked with a broken line) and Levosimendan
(unbroken line) groups. After release of the aortic occlusion, microcirculation increased to about 100% of baseline flux in the Levoismendan group, while
in IR group flux reached only 80% of the baseline measurements. Sham operated group is marked with a dotted line. Values are expressed as
means ± SD, ‡: p<0.001 vs. Sham, $: p<0.01 vs. IR, §: p<0.001 vs. IR.
doi:10.1371/journal.pone.0163675.g005
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skeletal muscle tissues. The serious injury of the skeletal muscle involves the risk for
Fig 6. Muscle viability. 4 hours after revascularization a marked decrease in viability was detected in the IR (ischemia-reperfusion) group, without any
sign of regeneration process 24 hours after reperfusion. Levosimendan administration resulted in significantly preserved viability compared to the IR
group at both measured time points (4 and 24 hours). Values are expressed as means ± SD, ‡: p<0.001 vs. Sham, §: p<0.001 vs. IR.
doi:10.1371/journal.pone.0163675.g006
Table 1. Laboratory measurements and calculated parameters for kidney function.
Sham 4h Sham 24h IR 4h Levo 4h p (IR vs
Levo)
IR 24h Levo 24h p (IR vs
Levo)
Creatinine[μmol/l] 30.912±4.449 29.675±8.781 97.850
±25.023
54.025±5.506 0.001 59.037±10.668 49.287±4.854 0.04
















FENa [%] 0.582±0.103 0.588±0.320 2.011±0.540 1.198±0.228 0.001 1.774±0.299 1.188±0.189 0.001
RFI [mmol/l] 0.799±0.076 0.801±0.239 2.616±0.387 1.657±0.168 0.001 2.333±0.204 1.611±0.157 0.001
Creatinine clearance 1.961± 0.596 - 0.199± 0.062 0.587± 0.165 0.001 - - -
Urine volume 1.013± 0.300 - 0.438± 0.177 0.738± 0.192 0.006 - - -
At the end of the fourth hour of reperfusion kidney injury was evident in the IR group. In contrast to Levosimendan group, where all of the measured and
calculated kidney function parameters showed significantly less expressed kidney injury. Renal failure index (RFI) and fractional sodium excretion (FENa)
indicated persistent kidney damage at the 24th hour after reperfusion with significantly lower values in the Levosimendan group. Values are given in each
subgroup as means ± SD. Abbreviations: FENa: fractional sodium excretion. RFI: renal failure index
doi:10.1371/journal.pone.0163675.t001
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postoperative systemic complications such as multiple organ failure.[23] The kidney is one of
the most exposed organ in this process, with serious clinical implications of postoperative kid-
ney dysfunction or even failure.[1] Many surgical and pharmacological techniques have been
introduced to minimize the degree of ischemia-reperfusion injury. Levosimendanmay be a
reasonable alternative of these approaches, considering the already known fair tolerability,
safety and well explored side-effect profile.[24, 25]
Besides its documented calcium sensitizer, positive inotropic and vasodilator properties
mainly used in severe low output heart failure,[3] levosimendan has also been demonstrated to
have a protective effect against ischemia-reperfusion injury via prevention of mitochondrial Ca2
+ overload,[26] and opening of KATP channels in the inner membrane of mitochondria.[10, 15]
The aim of our present study was to investigate the impact of levosimendan in a lower limb
IR model—that was previously utilized by our team—on local (muscle injuries) and systemic
(kidney failure) complications.[19]
In the present study levosimendan treatment was demonstrated to have a protective effect
against local IR injuries as evidencedby the skeletal muscle viability and muscle microcircula-
tion measurements. Hematoxylin and eosin staining under light microscopy failed to reveal
any detectablemorphological changes in this model. For assessment of subcellular lesions and
Fig 7. TNF-α concentration. TNF-α concentrations were significantly higher in the IR (ischemia-reperfusion) group compared to the Sham-
operated group after 4 hours of reperfusion. TNF-α levels were significantly less elevated by Levosimendan treatment after 4 hours of
reperfusion. 24 hours after reperfusion there were no significant differences among the three experimental groups. Values are expressed as
means ± SD, ‡: p<0.001 vs. Sham, §: p<0.001 vs. IR.
doi:10.1371/journal.pone.0163675.g007
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alterations in mitochondrial integrity, the viability of muscle fibers was assessed with a tech-
nique developed by our group.[22] Lower limb IR led to a significant reduction in the viability
of muscle cells, while levosimendan administration was able to preservemuscle viability com-
pared to the IR group.
In preservation of mitochondrial integrity by levosimendan, a couple of mechanisms may
be involved. Levosimendan is a potential activator of the ATP-sensitive potassium channels
(mitoKATP) of mitochondria[27, 28]. Opening of mitoKATP activates distal signaling pathways,
that involve improved defence against reactive oxygen species, protein-kinase Cε (PKCε),[12]
mitochondrial connexin 43 (Cx43)[11], and reperfusion injury survival kinases (the RISK path-
way),[27] which all converge for the prevention of opening of the mitochondrial permeability
transition pore (mPTP). Opening of these channels is linked to mitochondrial dysfunction via
dissipation of inner membrane potential, interruption of ATP synthesis, Ca2+ release, pyridine
nucleotide depletion,matrix swelling and a consequential rupture of the outer membrane and
release of proapoptotic proteins into the cytosol.[14]
The other important element of the protection of mitochondria is the regulation of cell’s cal-
cium homeostasis. After a prolonged episode of ischemia, the Na+/Ca2+ exchanger (NCX) of
the plasma membrane functions in a ‘reverse’ mode, resulting in Ca2+ influx to the cell. Over-
loading of calcium favors the pro-apoptotic Bcl2-associatedX (BAX) protein incorporation
into mitochondrial outer membrane that also leads to the opening of the mPTP.[29] It was
shown by Li et al that administration of levosimendan inhibited the reverse mode of NCX
activity, protecting the cadiomyocytes from Ca2+ overload.[26]
A less expressive IR injury in levosimendan treated animals was further confirmed by the
finding of a considerably less impaired muscle microcirculation after levosimendan adminis-
tration in contrast to the severely impaired muscle microcirculation in the IR group after revas-
cularization. This finding can be explained at least in part by the vasodilating effect of
levosimendan besides the positive impact on the limb tissues (muscle and a probable endothe-
lial cell) IR injury. The protective effect of levosimendan on skeletal muscle viability and micro-
circulation shares similarities with our previous findings of the protective effects of ischemic
postconditioning in the same model of limb IR injury.[19] Given the fact that levosimendan is
a mitoKATP agonist and that the signaling pathways of ischemic postconditioning also involves
the opening of the channel[11] it postulates a possible role of the channel opening in the effect
of levosimendan behind the present results.
A protective effect against lower limb injuries would gain clinical relevance mainly by the
impact it might have on the systemic complications of such injuries as for example the evolving
kidney failure. Accordingly, renal dysfunctionwas characterized in the present model.We
found that levosimendan administration resulted in milder histopathological alterations on
kidney samples, less serious renal dysfunction (less elevated serum creatinine, minor oliguria
and less impaired calculatedGFR) at the early post-revascularizationperiod, compared to the
group of animals that received no levosimendan infusion. This nephroprotective effect was pre-
served even 24 hours after reperfusion. Calculated clinical functional laboratory parameters
(fractional sodium excretion and serum carbamide/creatinine ratio) suggested a renal (tubular
injury) type impairment of renal function in the IR group. The significant difference between
the levosimendan treated and non-treated animals propose that levosimendan treatment
results in less expressed acute tubular injury. This effectmight be due to the ameliorated skele-
tal muscle IR injury, which resulted in less nephrotoxicity.
Our previous experimental and human investigations demonstrated a release of myoglobin
from the injured myocytes after vascular exclusion of the lower limbs.[19, 30] On one hand,
myoglobin interactions with Tamm-Horsfall proteins lead to tubular obstruction, on the other
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hand degradation and metabolism of myoglobin in tubular cells results in a heme-iron-medi-
ated lipid peroxidation process.[31, 32]
Although there seems to be a direct relationship between the lower limb rhabdomyolysis
and the acute kidney injury in our experiment, suggesting a direct toxic mechanism and an
acute tubular necrosis type of renal failure, we proposed a prerenal injury beside the acute
tubular necrosis. At revascularization of large skeletal muscles (previously exposed to hypoxia
and with injured microcirculation and vasorelaxation of the larger blood vessels) serious hemo-
dynamic changes evolve, even leading to shock, and a neuroendocrine response for circulatory
redistribution, both effecting kidney circulation.[1] On one side, levosimendan has been
described to improve perioperative cardiac performance[33] and may have beneficial effect in
cardiogenic[34] and even in septic shock[35] presumably by its positive inotropic action. On
the other side, by activation of vascular smooth muscle sarcolemmal KATP channels, this agent
is known to evoke vasodilatation, a decrease in vascular resistance and mean arterial pressure.
With detailed analysis of the systemic hemodynamic changes occurring in the present experi-
mental model we could not find any significant effect when levosimendan is applied during a
prolonged ischemia and revascularization of major lower limb arteries.
In contrast to the systemic hemodynamic parameters, infusion of levosimendan during
limb ischemia and revascularizationhad a marked effect regarding renal microcirculation. The
levosimendan treated animals presented a significantly less diminished cortical microcircula-
tion during reperfusion as opposed by the considerable reduction of blood flow in the IR
group. This circulatory impairment and the reduction of renal blood flow following skeletal
muscle ischemia-reperfusionmay arise from the systemic hemodynamic disturbances, the
compensation of renal vasoconstriction, but also from the toxic oxidoreductive effects of myo-
globin directly affecting renal microcirculation.[36] Levosimendanmay increase renal circula-
tion via preglomerular vasodilatation arising from its (sarcolemmal) KATP channel opening
properties on vascular smoothmuscle cells.[35, 37] All these contribute to the positive inotropy
exerted on the right ventricle of the heart and a consequential reduction of the central venous
and thus renal venous pressures.[38] Therefore, preglomerular vasodilationwith decreased
“right-sided” pressures lead to an improvement in renal blood flow and thus an increasedGFR.
Besides vasodilatation, levosimendan also attenuates the angiotensin II mediatedmesangial
cell contraction and thus increases the filtrating surface of glomeruli.[39]
Finally our results confirm the observations regarding the anti-inflammatory effect of levo-
simendan. TNF-α levels were significantly lower after 4 hours of reperfusion in the levosimen-
dan group compared to the IR group. 24 hours after reperfusion no differences could be
observed among the three experimental groups in serumTNF-α concentrations displaying the
temporal characteristics of the cytokin elevation. Acute inflammatory changes and TNF-αmay
also contribute to acute renal failure,[40, 41] and levosimendan has been previously shown to
exert anti-inflammatory effects,[42] the exact mechanisms of which are still not fully
understood.
Our study presents some new results offering new perspectives for the use of levosimendan.
We demonstrated that levosimendan treatment could protect muscle cells from ischemic injury
after 3 hours of ischemia. In addition to these local effects, levosimendan reduced the degree of
acute tubular kidney injury. An explanation of the positive effectsmay be the protection of
mitochondria via opening the KATP channels and the amelioration of the skeletal muscle ische-
mia-reperfusion injuries, which may lead to the prevention of the myoglobinuric acute renal
failure. The nephroprotective effect of the agent is further supported by the positive inotropic
and hemodynamic effects of levosimendan on the level of microcirculation and the possible
anti-inflammatory effect of the drug, confirmed in this study. These positive effects combined
might result in the preservation of renal function.
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Limitation of the study
The study is mostly descriptive in nature and does not provide information/evidence about cel-
lular changes during the process, most of the explanations and conclusions drawn are specula-
tive. With purpose of standardization, specific pathogen free, healthy maleWistar rats were
used only, so it is not suitable for detection the differences between genders and the population
is not comparable for patients with high risk cardiovascular diseases.Moreover the anatomical
differences (especially the circulatory system) makes the translation difficult, thus further,
mainly big-animal studies are required to eliminate these differences.
Supporting Information
S1 File. Minimal Data Sets.Minimal data sets of the experimentalmaterial supporting ‘Levo-
simendan administration in limb ischemia: multicomponent signaling serving kidney protec-
tion’ article, including heart rate, mean arterial pressure, kidney cortex as well as muscle
microcirculatory, muscle viability and labouratorymeasurements data, as broadly discussed
individually at respective sections of the article.
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